ArticleMolecular neuropsychiatry2018
Association of Novel ALX4 Gene Polymorphisms with Antidepressant Treatment Response: Findings from the CO-MED Trial.
Article in Molecular neuropsychiatry, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 12 citations in OpenAlex.
- Prenatal and postnatal challenges affect the hypothalamic molecular pathways that regulate hormonal levels.PloS one · 2023Article
- Precision Medicine in Antidepressants Treatment.Handbook of experimental pharmacology · 2023Review
- Multi-Omics Characterization of Early- and Adult-Onset Major Depressive Disorder.Journal of personalized medicine · 2022Article
- Network science approach elucidates integrative genomic-metabolomic signature of antidepressant response and lifetime history of attempted suicide in adults with major depressive disorder.Frontiers in pharmacology · 2022Article
- Multi-omics driven predictions of response to acute phase combination antidepressant therapy: a machine learning approach with cross-trial replication.Translational psychiatry · 2021Article
- Early pregnancy dyslipidemia is associated with placental DNA methylation at loci relevant for cardiometabolic diseases.Epigenomics · 2020Observational
- Pharmacogenetics and Depression: A Critical Perspective.Psychiatry investigation · 2019Article
- Moving pharmacoepigenetics tools for depression toward clinical use.Journal of affective disorders · 2019Review
- On the utilization of polygenic risk scores for therapeutic targeting.PLoS genetics · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
Abstract
Genome-wide association studies (GWAS) were conducted in participants of the CO-MED (Combining Medications to Enhance Depression Outcomes) trial, a randomized, 3-treatment arm clinical trial of major depressive disorder (MDD) designed to identify markers of differential treatment outcome (response and remission). The QIDS-SR (Quick Inventory of Depressive Symptomatology, Self-Reported version) was used to measure response at week 6 (QIDS-SR ≤5) and remission at week 12 (QIDS-SR ≤6 and ≤8 at the last two study visits). Three treatment groups (escitalopram monotherapy, escitalopram + bupropion, and venlafaxine + mirtazapine) were evaluated. GWAS identified a potentially regulatory SNP rs10769025 in the ALX4 gene on chromosome 11 with a strong association (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.